Abstracts tagged "osteoporosis"

Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 1563 • ACR Convergence 2024
Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
Gayane Matusov¹, Jon Giles² and Francesco Boin³, ¹Scripps Clinic, San Diego, CA, ²Cedars Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Case-control studies have shown that systemic sclerosis (SSc) patients exhibit higher prevalence of osteoporosis (OP) compared to subjects in the general population. The pathophysiology…
Abstract Number: 2132 • ACR Convergence 2024
A Quality Improvement Initiative to Increase Osteoporosis Screening in Internal Medicine Resident Led Primary Care Clinics
Ujjwal Madan¹, Tatiana Tselovalnikova¹, Sari Yordi², Kashvi Gupta², Muath Baniowda¹, Michael Pavlisin¹, Mohammad Adam¹, Julie Banderas¹, Sarah Ifteqar¹ and David Wooldridge¹, ¹University of Missouri Kansas City, Kansas City, MO, ²University of Missouri Kansas City, Kansas City
Background/Purpose: Osteoporosis increases morbidity and mortality of vulnerable individuals and adds to healthcare costs. The United States Preventive Services Task Force (USPSTF) recommends universal screening…
Abstract Number: 2528 • ACR Convergence 2024
Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis
Nagahiro Ochiai¹, Yuki Etani², Takaaki Noguchi², Taihei Miura², Takuya Kurihara², Yuji Fukuda², Hidetoshi Hamada², Keisuke Uemura², Kazuma Takashima², Masashi Tamaki², Teruya Ishibashi², Shohei Ito³, Satoshi Yamakawa², Takashi Kanamoto², Seiji Okada², Ken Nakata² and Kosuke Ebina², ¹Taisho Pharmaceutical Co., Ltd., Saitama, Saitama, Japan, ²Osaka University, Suita, Japan, ³Taisho Pharmaceutical, Co., Ltd., Saitama, Japan
Background/Purpose: This study investigated the diminished expression of Piezo1 (Piezo-type mechanosensitive ion channel component 1), a mechanosensitive receptor, in bone tissues of both patients and…
Abstract Number: 0490 • ACR Convergence 2024
Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
Abstract Number: 1748 • ACR Convergence 2024
Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Rachel Elam¹, Emma Kersey², Jing Li³, Gabriela Schmajuk⁴ and Laura Carbone⁵, ¹Augusta University, Evans, GA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Augusta University, Augusta, GA
Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA…
Abstract Number: 2133 • ACR Convergence 2024
Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better
Zeqin Wen¹, Yilun Wang¹, Xiaoxiao Li², Yuqing Zhang³, Junqing Xie⁴, Houchen Lyu⁵, Changjun Li², Jie Wei⁶, Guanghua Lei⁷ and Chao Zeng⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ²Central South University, Changsha, China (People's Republic), ³Massachusetts General Hospital, Quincy, MA, ⁴University of Oxford, Oxford, United Kingdom, ⁵Central South University, Beijing, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic)
Background/Purpose: High low-density lipoprotein cholesterol (LDL-C) is a major risk factor for fracture; however, whether LDL-C lowering induced by statins is associated with decreased fracture…
Abstract Number: 2564 • ACR Convergence 2024
Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study
Nneka Chukwu¹, Lillian Chang², Thomas Olenginski³, Hema Srinivasan⁴, Idorenyin Udoeyo², David Pugliese⁵, Andrea Berger² and Jonida Cote⁶, ¹Geisinger Medical Center, Danville, PA, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger, Lewisburg Pennsylvania 17837, PA, ⁴Geisinger Medical Center, Danvile, PA, ⁵Geisinger Health System, Wilkes-Barre, PA, ⁶Geisinger Medical Center, Orefield, PA
Background/Purpose: Osteoporosis remains poorly identified and treated. We studied the effects of an organized osteoporosis program of care on treatment rates over a 20-year period.…
Abstract Number: 0719 • ACR Convergence 2024
Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
Joanna El Hajj¹, Jennifer Waller¹, Yagni Patel¹, Wendy Bollag¹, Stephanie Baer² and Rachel Elam³, ¹Augusta University, Augusta, GA, ²VA Augusta Healthcare System, Augusta, GA, ³Augusta University, Evans, GA
Background/Purpose: End-stage renal disease (ESRD) secondary to vasculitis is linked to a higher risk of vertebral fractures compared to other causes of ESRD. It remains…
Abstract Number: 2112 • ACR Convergence 2024
Discontinuation and Non-Publication of Osteoporosis Studies: An Observational Analysis of 7,670,624 Patients
Mohamed Abdelsalam¹, Asmaa al-Najjar², omnia Samy³, Rawan morse⁴, roaa Rafat⁵ and Mona Sajed⁶, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories, ³Faculty of medicine - Zagazig university, Al Zagazig, Egypt, ⁴Medical Research Group of Egypt, Bur sa'id, Egypt, ⁵Faculty of medicine, Ahfad University for Women, Khartoum, Sudan, Cairo, Egypt, ⁶Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt
Background/Purpose: Osteoporosis (OP) is one of the most common diseases, especially in old age, and as the population ages, the burden of osteoporosis is expected…
Abstract Number: 2135 • ACR Convergence 2024
Disability, Functional Limitation, and Use of Anti-fracture Drug Therapies in a Cohort of 3651 U.S. Adults with Osteogenesis Imperfecta
Winnie liu¹, Jeffrey Curtis², Lars Folkestad³, Emily Holladay⁴, Ye Liu⁵, Fenglong Xie⁵, Jingyi Zhang⁵ and Eric Orwoll¹, ¹Oregon Health and Science University, Portland, OR, ²FASTER Medicine, Hoover, AL, ³University of Southern Denmark, Odense, Denmark, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Roughly 30,000 people are living with osteogenesis imperfecta (OI) in the US, most of them adults. Fractures rates are high in OI adults with minimal…
Abstract Number: 2565 • ACR Convergence 2024
A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis
Anna Strzelecka¹, Grzegorz Kania², Pawan Kumar Singh³, Kuldeep Kumar⁴, Binay Kumar Thakur³, Ashwani Marwah³, Sudipta Basu³, Nitin Madhukar Chaudhari³, Sarika S Deodhar³, Elena Wolff Holz³, Sandeep Nilkanth Athalye³ and Subramanian L⁵, ¹SOMED CR, Warszawa, Poland, ²ClinMedica Research Sp.zo.o, Skierniewice, Poland, ³Biocon Biologics Limited, Bengaluru, India, ⁴Biocon Biologics Limited,, Bengaluru, India, ⁵Biocon Biologics Limited, Bangalore, India
Background/Purpose: Osteoporosis, characterized by low bone mineral density (BMD) and micro-architectural deterioration of bone tissue, increases bone fragility and susceptibility to fractures. Denosumab, a fully…
Abstract Number: 2001 • ACR Convergence 2023
Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
Guy Katz¹, Aubree McMahon¹, Grace McMahon¹, Isha Jha¹, Marcy Bolster², Ana Fernandes¹, Zachary Wallace³, Cory Perugino¹, John Stone⁴ and Yasmin Hernandez-Barco¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Concord, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Metabolic bone disease (MBD), including osteopenia and osteoporosis, is common in patients with inflammatory disorders, due to disease factors and glucocorticoid (GC) use, and…
Abstract Number: 2018 • ACR Convergence 2023
Development of an Osteoporosis Treatment Gap Dashboard
Rulan Lyu¹, Patrick O'Brien¹, Tracey Wilkie¹, Yun Chang¹ and Jonathan Cheah², ¹UMass Memorial Health, Worcester, MA, ²UMass Chan Medical School, Shrewsbury, MA
Background/Purpose: Osteoporosis and the clinical event of fragility fracture is an ever-increasing public health burden. A significant osteoporosis treatment gap remains, whereby individuals with a…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].